---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-269635"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2026-06-12T20:55:55+00:00"
generated_at: "2026-06-12T20:58:56.211620+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Enliven Therapeutics prices upsized $400M public offering of common stock and pre-funded warrants

## Summary
- Priced 8,933,334 shares at $37.50/share and 1,733,333 pre-funded warrants at $37.499 each.
- Gross proceeds ~$400M; net proceeds ~$376M (or ~$432.4M if underwriters' option fully exercised).
- Underwriters granted 30-day option to purchase up to 1,600,000 additional shares.
- Offering expected to close June 15, 2026; joint book-runners: Jefferies, Goldman Sachs, Morgan Stanley, Barclays.
- Net proceeds for general corporate purposes and pipeline advancement (no specific allocation disclosed).

## SEC filing metadata
- accession: 0001193125-26-269635
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2026-06-12T20:55:55+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312526269635/0001193125-26-269635-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312526269635/d152122d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-269635
- JSON: https://secwatch.observer/filing/0001193125-26-269635.json
- Plain text: https://secwatch.observer/filing/0001193125-26-269635.txt

## Key facts
- Material Agreements
  Enliven Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Barclays Capital Inc. valued at approximately $376.0 million (effective 2026-06-11).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Jefferies LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Barclays Capital Inc.
  - Value: approximately $376.0 million
  - Effective: 2026-06-11
  source text: On June 11, 2026, Enliven Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Barclays Capital Inc. as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering (the “Offering”) of 8,933,334 shares of the Company’s common stock, par value $0.001 per share, at a price to the public of $37.50 per share (the “Firm Shares”), and, in lieu of Firm Shares to certain investors, pre-funded warrants to purchase 1,733,333 Shares (the “Pre-Funded Warrants”) at a price to the public of $37.499 per Pre-Funded Warrant, which represents the per share public offering price for the Firm Shares less the $0.001 exercise price for each such Pre-Funded Warrant.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312526269635/0001193125-26-269635-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.